You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

16 Results
Drug
Other Name(s): Tecvayli®
Jan 2025
Guidelines and Advice
Drug
Other Name(s): Trecondyv®
Jan 2025
Drug
Other Name(s): Tukysa™
Feb 2025
Drug
Other Name(s): Opdualag™
Feb 2025
Regimen
Cancer Type:
Lung, 
Small Cell
Intent: Palliative
Feb 2025
Drug
Other Name(s): Zejula
Mar 2025
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Adjuvant, Palliative
Funding:
Exceptional Access Program
    niraparib - For the maintenance treatment of newly diagnosed or recurrent high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, according to clinical criteria
Mar 2025
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal
Intent: Palliative
Updated
Mar 2025
Regimen
Cancer Type:
Genitourinary, 
Renal cell / Kidney
Intent: Palliative
Funding:
New Drug Funding Program
    Nivolumab plus Ipilimumab - Metastatic Renal Cell Carcinoma
New Drug Funding Program
    Nivolumab plus Ipilimumab - Metastatic Renal Cell Carcinoma
Updated
Mar 2025
Regimen
Intent: Adjuvant
Updated
Mar 2025

Pages